Business Context and Reporting Period
Company: Gilead Sciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: Gilead is a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapeutics for life-threatening diseases, primarily HIV, Hepatitis B, and fungal infections. The company operates globally with significant commercial presence in North America, Europe, and Australia.
Key Financial Metrics
| Metric | 2007 | 2006 | Change |
|---|---|---|---|
| Total Revenues | $4.23 billion | $3.03 billion | +39.8% |
| Product Sales | $3.73 billion | $2.59 billion | +44.2% |
| Royalty Revenues | $468.2 million | $416.5 million | +12.4% |
| Net Income | $1.62 billion | ($1.19 billion) Loss | Turnaround |
| Diluted EPS | $1.68 | ($1.30) | N/A |
| Product Gross Margin | 79% | 83% | -4 pts |
| R&D Expenses | $591.0 million | $383.9 million | +53.9% |
| Cash & Equivalents | $2.72 billion | $1.39 billion | +96% |
| Convertible Debt | $1.30 billion | $1.30 billion | 0% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 40% driven by a 48% surge in HIV product sales. Truvada sales grew 33% to $1.59 billion, and Atripla sales grew 339% to $903 million following its 2006 launch.
- Profitability Turnaround: The company reported a net income of $1.62 billion in 2007, reversing a net loss of $1.19 billion in 2006. The 2006 loss was primarily due to $2.39 billion in non-cash charges for purchased in-process research and development (IPR&D) from the acquisitions of Myogen and Corus.
- Margin Compression: Product gross margin decreased from 83% to 79%. This decline is attributed to the increasing sales mix of Atripla, which includes a component (Sustiva) supplied by partner Bristol-Myers Squibb at zero gross margin to Gilead.
- R&D Investment: R&D expenses increased 54% to $591 million, reflecting expanded clinical trials for HIV, Hepatitis C, and respiratory/cardiovascular candidates, as well as upfront license fees for new technologies.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- 2008 Expectations: Management expects product sales to continue growing in 2008. However, royalty revenues are expected to decline significantly due to a projected drop in Tamiflu sales by partner Roche following the fulfillment of pandemic stockpiling orders.
- Product Pipeline: Key milestones include the anticipated approval of Viread for Hepatitis B and aztreonam lysine for inhalation for Cystic Fibrosis. The company is advancing elvitegravir (HIV integrase inhibitor) into Phase 3 trials.
- Capital Allocation: The company completed a $1 billion stock repurchase program in 2007 and initiated a new $3 billion repurchase program in October 2007.
Risks and Contingencies
- Product Concentration: HIV products accounted for 74% of total revenues in 2007. A change in treatment paradigms or safety issues could materially impact results.
- Tamiflu Royalty Volatility: While Tamiflu royalties represented less than 10% of total revenue, they accounted for 18% of pre-tax income. A decline in Tamiflu sales will disproportionately affect pre-tax income.
- Patent Challenges: The Public Patent Foundation filed requests for re-examination of four patents related to tenofovir (active ingredient in Truvada, Atripla, Viread). The outcome is uncertain.
- Regulatory and Safety: Letairis (PAH treatment) faces safety monitoring requirements (liver injury, birth defects) and is distributed via a restricted program. Generic competition is anticipated for Flolan as patent protection expires.
- European Credit Risk: Significant accounts receivable balances exist in Greece, Italy, Portugal, and Spain due to government reimbursement delays.
Investor Verification Checklist
- Tamiflu Royalty Trajectory: Verify the magnitude of the expected decline in Tamiflu royalties from Roche for 2008 and its specific impact on pre-tax income.
- Atripla Mix Impact: Monitor the ratio of Atripla sales to total HIV sales to assess the trajectory of gross margin compression.
- Patent Re-examination Status: Track the status of the PTO re-examination proceedings regarding tenofovir patents.
- European Receivables: Review the aging of accounts receivable in Southern Europe (Greece, Italy, Portugal, Spain) and the adequacy of the allowance for doubtful accounts.
- Regulatory Approvals: Confirm the approval status and launch timelines for Viread (Hepatitis B) and aztreonam lysine (Cystic Fibrosis).